Herzuma clinical trials
A product of Trastuzumab; its studies count on that page too.
How each study uses Herzuma has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Herzuma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 25 Sept 1998 · HERCEPTIN · BLA 103792 (FDA, Drugs@FDA; as Trastuzumab)
- European Union
- 28 Aug 2000 · Herceptin · EMEA/H/C/000278 (EMA; as Trastuzumab)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Herzuma
- 3
Studies by the year they started
5 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
National Cancer Center, Korea (1) · Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia (1) · Gangnam Severance Hospital (1) · Samsung Medical Center (1) · Korean Cancer Study Group (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A biosimilar of Trastuzumab
Studies
Open first, then newest update. How each study uses Herzuma has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)RecruitingPhase 2Gangnam Severance HospitalNCT04817540Written as HerzumaReport a problem
- Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast CancerCompletedPhase 2National Cancer Center, KoreaNCT03755141Written as HerzumaReport a problem
- Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical PracticeCompletedNot applicableFundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaNCT06907082Written as Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.Report a problem
- Combination of Nanoxel and Herzuma in Salivary Duct CarcinomaStatus unknownPhase 2Samsung Medical CenterNCT03614364Written as herzumaReport a problem
- Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast CancerStatus unknownPhase 2Korean Cancer Study GroupNCT03698383Written as Trastuzumab biosimilars(Herzuma), GedatolisibReport a problem
Tested on its own · 3 — no other medicine in its arm
- Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)RecruitingPhase 2Gangnam Severance HospitalNCT04817540Written as HerzumaReport a problem
- Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast CancerCompletedPhase 2National Cancer Center, KoreaNCT03755141Written as HerzumaReport a problem
- Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast CancerStatus unknownPhase 2Korean Cancer Study GroupNCT03698383Written as Trastuzumab biosimilars(Herzuma), GedatolisibReport a problem
Tested in a combination · 2 — another drug in the study is under test too
- Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical PracticeCompletedNot applicableFundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaNCT06907082Written as Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.Report a problem
- Combination of Nanoxel and Herzuma in Salivary Duct CarcinomaStatus unknownPhase 2Samsung Medical CenterNCT03614364Written as herzumaReport a problem